These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 31674267

  • 1. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
    Jolly M, Annapureddy N, Arnaud L, Devilliers H.
    Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
    [Abstract] [Full Text] [Related]

  • 2. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76).
    Rendas-Baum R, Baranwal N, Joshi AV, Park J, Kosinski M.
    J Patient Rep Outcomes; 2021 Apr 08; 5(1):33. PubMed ID: 33830377
    [Abstract] [Full Text] [Related]

  • 3. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug 08; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 4. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups.
    Ann Rheum Dis; 2012 Nov 08; 71(11):1833-8. PubMed ID: 22550315
    [Abstract] [Full Text] [Related]

  • 5. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA, Martin RS, Scheinberg MA, Furie RA.
    Lupus; 2017 Jan 08; 26(1):27-37. PubMed ID: 27353505
    [Abstract] [Full Text] [Related]

  • 6. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar 08; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 08; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 8. Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.
    Furie R, Wang L, Illei G, Drappa J.
    Lupus; 2018 May 08; 27(6):955-962. PubMed ID: 29460699
    [Abstract] [Full Text] [Related]

  • 9. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
    Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S.
    Arthritis Care Res (Hoboken); 2019 Jun 08; 71(6):829-838. PubMed ID: 30320964
    [Abstract] [Full Text] [Related]

  • 10. Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.
    Giangreco D, Devilliers H, Annapureddy N, Block JA, Jolly M.
    Lupus; 2015 Dec 08; 24(14):1486-91. PubMed ID: 26162686
    [Abstract] [Full Text] [Related]

  • 11. The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.
    Devilliers H, Bonithon-Kopp C, Jolly M.
    Lupus; 2017 Apr 08; 26(4):396-402. PubMed ID: 27587460
    [Abstract] [Full Text] [Related]

  • 12. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS).
    Chaigne B, Chizzolini C, Perneger T, Trendelenburg M, Huynh-Do U, Dayer E, Stoll T, von Kempis J, Ribi C, Swiss Systemic Lupus Erythematosus Cohort Study Group.
    BMC Immunol; 2017 Mar 28; 18(1):17. PubMed ID: 28351341
    [Abstract] [Full Text] [Related]

  • 13. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C, Medina-Rosas J, Santos AM, Jaimes DA, Arbeláez AM, Romero C, Cortes A, Londono J.
    J Rheumatol; 2016 Sep 28; 43(9):1657-64. PubMed ID: 27134246
    [Abstract] [Full Text] [Related]

  • 14. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Lupus Sci Med; 2014 Sep 28; 1(1):e000031. PubMed ID: 25396065
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 28; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 16. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 28; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 18. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1143-51. PubMed ID: 19714615
    [Abstract] [Full Text] [Related]

  • 19. Feasibility, Validity, and Reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in Outpatients with Systemic Lupus Erythematosus.
    Kasturi S, Szymonifka J, Burket JC, Berman JR, Kirou KA, Levine AB, Sammaritano LR, Mandl LA.
    J Rheumatol; 2018 Mar 15; 45(3):397-404. PubMed ID: 29419473
    [Abstract] [Full Text] [Related]

  • 20. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups.
    Ann Rheum Dis; 2014 May 15; 73(5):838-44. PubMed ID: 23524886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.